Daily Cosmetic Research Analysis
Analyzed 34 papers and selected 3 impactful papers.
Summary
Analyzed 34 papers and selected 3 impactful articles.
Selected Articles
1. Vacuum-assisted excision versus open surgery for intraductal lesions: a systematic review and meta-analysis of therapeutic effectiveness, safety, and patient-reported outcomes.
Across 26 studies, vacuum-assisted excision matched open surgery in residual lesion rates while reducing recurrence, operative time, blood loss, and complications, and improving cosmetic satisfaction and pain scores. The evidence supports VAE as a minimally invasive option for radiologically localized intraductal lesions, while open surgery remains crucial for malignant/high-risk scenarios.
Impact: This synthesis integrates oncologic, perioperative, and patient-reported outcomes, offering a comprehensive framework for individualized selection between VAE and open surgery.
Clinical Implications: For localized intraductal lesions, VAE can be prioritized to enhance recovery and cosmetic satisfaction without compromising lesion control, while ensuring oncologic safety by reserving open surgery for high-risk or malignant indications.
Key Findings
- No significant difference in residual lesion rates between VAE and open surgery (RR 1.02; 95% CI 0.29-3.57; P=0.97).
- VAE reduced recurrence by 59% compared with open surgery (RR 0.43; 95% CI 0.21-0.86; P=0.02).
- Shorter operative time with VAE (MD -14.38 min; 95% CI -17.09 to -11.67; P<0.01) and less blood loss (MD -9.10 mL; 95% CI -11.29 to -6.92; P<0.01).
- Lower risks of skin ecchymosis (RR 0.43), wound infection (RR 0.31), and breast deformity (RR 0.19) with VAE.
- Higher cosmetic satisfaction (RR 1.34; P<0.001) and lower postoperative pain (MD -1.61) in VAE groups.
Methodological Strengths
- Systematic synthesis with meta-analysis across 26 studies, reporting effect sizes (RR, MD) with 95% CIs.
- Explicit inclusion of patient-reported outcomes (cosmetic satisfaction, pain) alongside oncologic and safety endpoints.
Limitations
- Insufficient direct comparative data on malignancy detection rates; no pooled analysis to establish diagnostic superiority.
- Potential heterogeneity of included studies and predominance of nonrandomized designs.
Future Directions: Prospective comparative studies with standardized PROs and oncologic endpoints, and stratification by lesion risk, are needed to refine indications and confirm long-term outcomes.
BACKGROUND: Surgical decision-making for intraductal breast lesions has traditionally relied on physician expertise and imaging characteristics, lacking a comprehensive evaluation framework that integrates oncological efficacy, perioperative safety, and patient subjective experience. This study aimed to systematically synthesise the latest evidence and incorporate patient-reported outcomes (PROs) to construct a three-dimensional evaluation model, thereby providing an evidence base for the individualised selection between vacuum-assisted excision (VAE) and open surgery. METHODS: A systematic comparison and descriptive analysis were performed across three dimensions: oncological efficacy, perioperative safety, and PROs. A total of 26 studies were included. RESULTS: Meta-analysis revealed no significant difference in residual lesion rates between the VAE and open surgery groups [risk ratios (RR) =1.02; 95% confidence interval (CI): 0.29-3.57; P=0.97]. Notably, the VAE group demonstrated a 59% significant reduction in recurrence rates (RR =0.43; 95% CI: 0.21-0.86; P=0.02). Due to the lack of direct comparative data, malignancy detection rates were presented descriptively without statistical pooling, and no inferences regarding diagnostic superiority were drawn. Regarding perioperative safety, VAE was associated with a significantly shorter operative time [mean difference (MD) =-14.38 min; 95% CI: -17.09 to -11.67; P<0.01] and reduced intraoperative blood loss (MD =-9.10 mL; 95% CI: -11.29 to -6.92; P<0.01). Furthermore, VAE significantly lowered the risks of skin ecchymosis (RR =0.43; 95% CI: 0.20-0.95; P=0.04), wound infection (RR =0.31; 95% CI: 0.14-0.69; P=0.004), and breast deformity (RR =0.19; 95% CI: 0.05-0.74; P=0.02). For PROs, patients in the VAE group reported significantly higher cosmetic satisfaction (RR =1.34; 95% CI: 1.15-1.56; P<0.001) and lower postoperative pain scores (MD =-1.61; 95% CI: -2.68 to -0.54; P=0.003). CONCLUSIONS: VAE offers clear benefits such as being minimally invasive, supporting postoperative recovery, and improving cosmetic satisfaction, making it a preferred method for radiologically localised lesions. However, current evidence is insufficient to confirm VAE as a definitive treatment for malignant or high-risk intraductal conditions. Open surgery remains essential to ensure oncological safety through thorough margin assessment and accurate detection of malignancy; the potential clinical consequences of missing malignancy greatly outweigh minor cosmetic outcomes. Future treatment options should be guided by personalised decision-making that considers lesion characteristics and patient preferences.
2. Hypersensitivity Reactions to Injectable Fillers and Their Impact on Cosmetic Procedure Results.
In a prospective 92-patient cohort, 22.8% experienced hypersensitivity to dermal fillers, predominantly delayed type IV reactions (13%) occurring 5–14 days post-injection. Reactions were more frequent with calcium hydroxyapatite and polycaprolactone fillers and were associated with lower patient satisfaction and aesthetic complications.
Impact: Provides prospective incidence and phenotype data linking filler type to hypersensitivity and quantifies the adverse impact on aesthetic outcomes.
Clinical Implications: Risk stratify by filler type, counsel on delayed reactions, and extend monitoring beyond 2 weeks; prepare management pathways for type I and IV hypersensitivity, including systemic therapy when indicated.
Key Findings
- Overall hypersensitivity incidence was 22.8% (21/92).
- Delayed type IV reactions predominated (13.0%; onset 5–14 days), while immediate type I occurred in 9.8% within 72 hours.
- Higher reaction rates with calcium hydroxyapatite and polycaprolactone fillers compared with hyaluronic acid.
- Severe reactions often had elevated IgE and required systemic therapy.
- Patient satisfaction (VAS) was significantly lower in the reaction group (5.9 ± 1.8 vs. 8.4 ± 1.1; p < 0.01); all aesthetic complications occurred in those with hypersensitivity.
Methodological Strengths
- Prospective design with predefined follow-up at days 3, 7, 14, and 30.
- Standardized classification of hypersensitivity (Gell-Coombs) and inclusion of laboratory correlates.
Limitations
- Single-center study with short (30-day) follow-up and modest sample size.
- Product mix and injection techniques may confound reaction rates; no long-term outcomes.
Future Directions: Multicenter studies with longer follow-up, mechanistic assays (e.g., impurity profiling), and standardized outcome measures to inform prevention and management algorithms.
BACKGROUND: Injectable dermal fillers are widely used in aesthetic medicine; however, immunologically mediated hypersensitivity reactions may negatively influence clinical and aesthetic outcomes. Understanding their incidence, clinical presentation, and consequences is essential for improving patient safety and treatment effectiveness. OBJECTIVE: To evaluate the incidence, clinical characteristics, and impact of hypersensitivity reactions on aesthetic outcomes after dermal filler injections. METHODS: A prospective observational study included 92 patients aged 25-64 years who underwent cosmetic filler injections at an aesthetic clinic in Poland between November and December 2024. The fillers used included hyaluronic acid, calcium hydroxyapatite, and polycaprolactone-based preparations. Patients were monitored for 30 days with follow-up visits on days 3, 7, 14, and 30. Hypersensitivity reactions were classified according to the Gell-Coombs classification (types I and IV). Clinical manifestations, severity, and laboratory parameters (IgE, C-reactive protein, and procalcitonin) were evaluated in selected cases. Aesthetic outcomes were assessed using the Global Aesthetic Improvement Scale (GAIS) and a Visual Analogue Scale (VAS) of patient satisfaction. RESULTS: Hypersensitivity reactions occurred in 21 patients (22.8%). Delayed type IV reactions predominated (13.0%) and manifested with infiltrates, erythema, and pain occurring 5-14 days after injection, whereas immediate type I reactions were recorded in 9.8% of patients within the first 72 h. The highest reaction rates were observed with calcium hydroxyapatite and polycaprolactone fillers. Severe reactions required systemic therapy and were associated with elevated IgE levels in most cases. Patient satisfaction was significantly lower in the reaction group (VAS 5.9 ± 1.8 vs. 8.4 ± 1.1; p < 0.01). All reported aesthetic complications, including fibrosis and hyperpigmentation, occurred exclusively in patients with hypersensitivity reactions. CONCLUSION: Hypersensitivity reactions to dermal fillers occur relatively frequently and significantly affect aesthetic outcomes and patient satisfaction. Individual risk assessment, careful filler selection, and extended post-procedure monitoring are necessary to minimise complications. LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
3. Metals and metalloids contamination in injectable hyaluronic acid dermal fillers: Multi-element evidence of market variability.
ICP-MS profiling of 19 hyaluronic acid fillers across price tiers showed distinct multi-element impurity fingerprints, with several metals/metalloids displaying strong price-related gradients (e.g., decreasing mean aluminum with higher price). Statistical and multivariate analyses support market variability with potential relevance to delayed inflammatory and hypersensitivity reactions.
Impact: Offers multi-element, market-wide impurity evidence in HA fillers and links it conceptually to clinical hypersensitivity, informing procurement, regulation, and research into adverse reactions.
Clinical Implications: Clinicians should consider product quality variability when selecting fillers, counsel patients on potential delayed reactions, and report adverse events; regulators may leverage impurity benchmarks to refine standards.
Key Findings
- ICP-MS quantified 22 elements across 19 HA fillers categorized by price (low/mid/premium).
- Several elements exhibited strong price-related gradients; mean aluminum content decreased with higher price tiers.
- Multivariate analyses (PCA, heatmaps, correlations) revealed distinct impurity fingerprints among products.
- Findings are pertinent to delayed inflammatory and hypersensitivity reactions associated with fillers.
Methodological Strengths
- Robust multi-element quantification via ICP-MS with appropriate group comparisons (ANOVA/Tukey).
- Use of multivariate techniques (PCA, heatmaps) to delineate impurity fingerprints.
Limitations
- Limited sample of 19 products and potential batch/manufacturer variability not fully addressed.
- No direct clinical correlation to adverse events; cross-sectional design.
Future Directions: Link impurity profiles to clinical registries of filler complications, expand product sampling across batches, and define regulatory impurity thresholds.
Injectable hyaluronic acid (HA) dermal fillers are widely used medical devices, yet data on their elemental impurity profiles remain limited despite the potential relevance of metals/metalloids to delayed inflammatory and hypersensitivity reactions. The aim of this study was to determine the multi-element impurity profiles of commercially available HA fillers and to evaluate whether product price category is associated with elemental content. Nineteen HA fillers were divided into low- (LP), mid- (MP), and premium-price (PP) groups and analyzed by inductively coupled plasma mass spectrometry (ICP-MS) for 22 elements. Group differences (ANOVA/Tukey) and multivariate patterns (PCA, heatmaps, correlations) were used to compare impurity fingerprints across products. Several elements showed strong price-related gradients. Mean Al content decreased from 4200 mg kg